Business / Finance

RSS

CryoLife reaches full settlement in Medafor lawsuit

CryoLife, Inc., a leading medical device company focused on cardiac and vascular surgery, announced today that it has reached full settlement of the outstanding CryoLife, Inc. v. Medafor, Inc. lawsuit that was pending in the Northern District Court of Georgia.

15 Jun 2012

Johnson & Johnson acquires Synthes

Johnson & Johnson today announced the completion of the acquisition of Synthes, Inc. for a total purchase price of $19.7 billion in cash and stock. Synthes will now be integrated with the DePuy franchise to establish the DePuy Synthes Companies of Johnson & Johnson.

15 Jun 2012

Invuity closes $25M Series D round of financing

Invuity, a leading developer of state-of-the-art surgical visualization and illumination technology, has raised a $25 million Series D round of financing to expand the development, manufacturing and commercialization of the company's advanced medical devices.

14 Jun 2012

Medical Action fourth quarter net sales increase 3% to $108.2 million

Medical Action Industries Inc., a leading supplier of medical and surgical disposable products, today reported results for the fourth quarter and fiscal year ended March 31, 2012.

14 Jun 2012

UHCO alumnus donate $5 million to University of Houston

University of Houston College of Optometry (UHCO) alumnus Dr. Doug Barnes and his wife, Molly, have made a $5 million pledge to the University of Houston. The gift will be submitted for state matching funds through the Texas Research Incentive Program.

14 Jun 2012

EvaluatePharma releases World Preview 2018 report

EvaluatePharma, the premier provider of pharmaceutical and biotech analysis including consensus forecasts, today released its World Preview 2018 report, providing an in-depth look at how the patent cliff will reshape the drug industry over the next six years — with valuable insight into which companies and products will come out as winners.

14 Jun 2012

Igenica raises $33M in Series C round of funding

Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding.

12 Jun 2012

Enzo Biochem third quarter total revenue increases 4% to $26 million

Enzo Biochem, Inc. today reported results for the fiscal third quarter ended April 30, 2012.

12 Jun 2012

BioMed Realty enters definitive agreement to acquire Granta Park

BioMed Realty Trust, Inc. today announced that it has entered into a definitive agreement to acquire Granta Park, comprising eleven laboratory and office buildings and a total of approximately 472,200 square feet of space, as well as approximately 138,400 square feet of development and expansion rights, in Cambridge, United Kingdom. The purchase price for the property is 126.8 million pounds, or approximately $196.0 million, excluding transaction costs.

11 Jun 2012

Prime Health Services announces acquisition of Casualty Management Network

Prime Health Services (Prime), one of the nation's largest workers' compensation, group health, corrections, and auto liability PPO networks is pleased to announce it has acquired Casualty Management Network (CMN).

11 Jun 2012

Cambridge facility to become worldwide hub for SAFC's chiral service

Sigma-Aldrich Corporation today announced that its custom manufacturing and services business unit, SAFC, will consolidate its global chiral chromatography screening and small scale purification operations and locate them at its Pharmorphix Solid State Research Laboratories in Cambridge, UK, to support its new integrated chiral chemistry offer.

11 Jun 2012

Sagard Capital to acquire IntegraMed

IntegraMed America, Inc., a leader in developing, marketing and managing specialty healthcare facilities in the fertility and vein care markets, announced today that it has entered into a definitive agreement to be acquired by affiliates formed by Sagard Capital Partners, L.P., an investment fund and IntegraMed shareholder, for $14.05 per share in cash, or a total equity purchase price of $169.5 million.

11 Jun 2012

Novelos announces pricing of public offering

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced the pricing of a public offering of 5,420,800 units at $1.00 per unit for gross proceeds of $5,420,800.

8 Jun 2012

Astute Medical announces completion of $40.4M Series C financing

Astute Medical, Inc., a developer of novel, biomarker-based medical diagnostics, today announced the completion of a $40.4 million Series C financing led by MPM Capital and including new investor Kaiser Permanente Ventures.

7 Jun 2012

Streamline Health first quarter revenues increase to $5,445,000

Streamline Health Solutions, Inc. today announced financial results for the first quarter of fiscal year 2012, ended April 30, 2012.

7 Jun 2012

$6.4 million awarded to investigate mechanisms of allergy tolerance generated by Circassia’s ToleroMune Treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the United States’ National Institutes of Health (NIH) has awarded a $6.4 million grant to Professor Mark Larché of McMaster University, Canada, to study mechanisms of tolerance developed by patients treated with Circassia’s Toleromune® allergy therapy.

7 Jun 2012

Sectra announces acquisition of Burnbank

IT and medical technology company Sectra is expanding through the acquisition of Burnbank Systems Limited, which markets IT services to the healthcare sector in the UK.

7 Jun 2012

End-to-end regulatory solution for medical device companies in Europe offered by new partnership between ELC and mdi Europa

ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation, today announces that it has formed a preferred European partner relationship with mdi Europa GmbH, a global regulatory consultancy for medical device and IVD companies.

6 Jun 2012

PhaseBio raises $48.4M in Series B financing

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has raised a total of $48.4 million from its Series B financing following receipt of the third tranche to advance the company's product development programs.

6 Jun 2012

inVentiv Health acquires Kazaam Interactive

inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that it has acquired Kazaam Interactive, a full-service interactive agency providing comprehensive solutions and services for healthcare agencies and brands.

6 Jun 2012